Skip to content

A 12-month, multicenter, randomized, double-blind, parallel-group trial for assessment of the short-term effect and long-term prognosis of sequential discontinuation and direct discontinuation after the application of systemic corticosteroids in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD)

A 12-month, multicenter, randomized, double-blind, parallel-group for assessment of the short-term effect and long-term prognosis of sequential discontinuation and direct discontinuation after the application of systemic corticosteroids in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD).

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800018894
Enrollment
Unknown
Registered
2018-10-16
Start date
2018-10-20
Completion date
Unknown
Last updated
2018-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AECOPD

Interventions

Group 1:Methylprednisone was used 40mg/ day for 5 days, and methyl prednisone was discontinued after expiration
Group 2:Methylprednisone 40mg/ day, continuous use for 5 days, gradually reduce after maturity, reduce 10mg every 2 days, and stop using methyl prednisone at 10 days

Sponsors

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. patients aged 40-70 years; 2. patients with AECOPD (patients complained of symptoms of sudden changes (baseline dyspnea, cough, and/or sputum) more than the daily variation range of patients with COPD (always check lung function: with bronchial relaxation, FEV1 / FVC < 0.70)); 3. The subjects should be volunteers and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. patients with AECOPD in a critical condition, in which the auxiliary breathing muscles participate in respiratory movement, chest and abdomen contradictory breathing, cyanosis, and invasive mechanical ventilation are required; 2. patients with concomitant signs of lower limb edema, right heart failure and hemodynamic instability; 3. patients with merge spiritual changes; 4. patients with malignant tumors or other serious diseases.

Design outcomes

Primary

MeasureTime frame
clinical symptoms;pulmonary function test;blood routine examination;

Secondary

MeasureTime frame
blood gas analysis;Serum inflammatory markers;FeNO;phlegma;Echocardiography;CT Scan of the Lungs;Rating scales;Medication;

Countries

China

Contacts

Public ContactLiu Huiguo

Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

liuhuiguotj@139.com+86 13871014148

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026